Hericenone DCAS# 137592-04-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 137592-04-2 | SDF | Download SDF |
| PubChem ID | 15658906.0 | Appearance | Powder |
| Formula | C37H58O6 | M.Wt | 598.87 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [4-[(2E)-3,7-dimethyl-5-oxoocta-2,6-dienyl]-2-formyl-3-hydroxy-5-methoxyphenyl]methyl octadecanoate | ||
| SMILES | CCCCCCCCCCCCCCCCCC(=O)OCC1=CC(=C(C(=C1C=O)O)CC=C(C)CC(=O)C=C(C)C)OC | ||
| Standard InChIKey | ZTJZNRQMSBGEOJ-JBASAIQMSA-N | ||
| Standard InChI | InChI=1S/C37H58O6/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-36(40)43-28-31-26-35(42-5)33(37(41)34(31)27-38)23-22-30(4)25-32(39)24-29(2)3/h22,24,26-27,41H,6-21,23,25,28H2,1-5H3/b30-22+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Hericenone D Dilution Calculator
Hericenone D Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6698 mL | 8.3491 mL | 16.6981 mL | 33.3962 mL | 41.7453 mL |
| 5 mM | 0.334 mL | 1.6698 mL | 3.3396 mL | 6.6792 mL | 8.3491 mL |
| 10 mM | 0.167 mL | 0.8349 mL | 1.6698 mL | 3.3396 mL | 4.1745 mL |
| 50 mM | 0.0334 mL | 0.167 mL | 0.334 mL | 0.6679 mL | 0.8349 mL |
| 100 mM | 0.0167 mL | 0.0835 mL | 0.167 mL | 0.334 mL | 0.4175 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2'-O-Methylisomucronulatol
Catalog No.:BCX0973
CAS No.:2243403-57-6
- 7,2'-Dimethoxyisomucronulatol
Catalog No.:BCX0972
CAS No.:60478-76-4
- (1R,4E,9E,11S)-4,12,12-trimethyl-8-oxobicyclo[9.1.0]dodeca-4,9-dien-2-yl acetate
Catalog No.:BCX0971
CAS No.:1350083-66-7
- 4-Desoxypicropodophyllotoxin
Catalog No.:BCX0970
CAS No.:24150-39-8
- Cyanidin3-(6-(2-(E)-sinapoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-5-(6-(E)-sinapoyl)-β-D-glucopyranoside
Catalog No.:BCX0969
CAS No.:1978410-75-1
- Cyanidin3-(6-(E)-coumarin)-(2-(E)-sinapoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-5-glucopyranoside
Catalog No.:BCX0968
CAS No.:117894-45-8
- Cyanidin3-(6-(2-(p)-coumarate-β-D-glucopyranosyl)-β-D-glucopyranosyl)-5-glucopyranoside
Catalog No.:BCX0967
CAS No.:771448-35-2
- Cyanidin3-O-(6-O-(E)-Feruloyl-β-D-glucopyranosyl(2-O-(E)-Feruloyl-β-D-glucopyranosyl)-glucopyranoside-5-O-glucopyranoside
Catalog No.:BCX0966
CAS No.:942192-63-4
- Cyanidin3-O-(6-(E)-Feruloyl)-β-D-glucopyranoside-(2-O-(E)-sinapoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl-5-glucopyranoside
Catalog No.:BCX0965
CAS No.:765863-34-1
- Gancaonin L
Catalog No.:BCX0964
CAS No.:129145-50-2
- Glyurallin B
Catalog No.:BCX0963
CAS No.:199331-53-8
- IsochlorogenicacidA 3,5-Dicaffeoylquinicacid
Catalog No.:BCX0962
CAS No.:89919-62-0
- Hericenone C
Catalog No.:BCX0975
CAS No.:137592-03-1
- Hericene C
Catalog No.:BCX0976
CAS No.:157207-56-2
- Carpaine
Catalog No.:BCX0977
CAS No.:3463-92-1
- 1,2-Disinapoylgentiobiose
Catalog No.:BCX0978
CAS No.:195006-75-8
- Celosin H
Catalog No.:BCX0979
CAS No.:1623405-28-6
- Testosterone enantate impurity H
Catalog No.:BCX0980
CAS No.:162890-98-4
- Oseltamivir impurity A
Catalog No.:BCX0981
CAS No.:1364932-19-3
- Dosulepin impurity A
Catalog No.:BCX0982
CAS No.:42046-35-5
- Celosin L
Catalog No.:BCX0983
CAS No.:1950581-97-1
- Caffeic acid 4-O-glucopyranoside
Catalog No.:BCX0984
CAS No.:17093-82-2
- 1,2-Disinapoylglucose
Catalog No.:BCX0985
CAS No.:91095-79-3
- Notoginsenoside R3
Catalog No.:BCX0986
CAS No.:87741-76-2
Neuroprotective Metabolites of Hericium erinaceus Promote Neuro-Healthy Aging.[Pubmed:34203691]
Int J Mol Sci. 2021 Jun 15;22(12):6379.
Frailty is a geriatric syndrome associated with both locomotor and cognitive decline, typically linked to chronic systemic inflammation, i.e., inflammaging. In the current study, we investigated the effect of a two-month oral supplementation with standardized extracts of H. erinaceus, containing a known amount of Erinacine A, Hericenone C, Hericenone D, and L-ergothioneine, on locomotor frailty and cerebellum of aged mice. Locomotor performances were monitored comparing healthy aging and frail mice. Cerebellar volume and cytoarchitecture, together with inflammatory and oxidative stress pathways, were assessed focusing on senescent frail animals. H. erinaceus partially recovered the aged-related decline of locomotor performances. Histopathological analyses paralleled by immunocytochemical evaluation of specific molecules strengthened the neuroprotective role of H. erinaceus able to ameliorate cerebellar alterations, i.e., milder volume reduction, slighter molecular layer thickness decrease and minor percentage of shrunken Purkinje neurons, also diminishing inflammation and oxidative stress in frail mice while increasing a key longevity regulator and a neuroprotective molecule. Thus, our present findings demonstrated the efficacy of a non-pharmacological approach, based on the dietary supplementation using H. erinaceus extract, which represent a promising adjuvant therapy to be associated with conventional geriatric treatments.
Characterization of alpha-glucosidase inhibitory constituents of the fruiting body of lion's mane mushroom (Hericium erinaceus).[Pubmed:32738392]
J Ethnopharmacol. 2020 Nov 15;262:113197.
ETHNOPHARMACOLOGICAL RELEVANCE: Hericium erinaceus, commonly called lion's mane mushroom, is an edible and medicinal mushroom that has been traditionally used for the treatment of metabolic disorders, gastrointestinal diseases and memory impairment. In this study, potential anti-hyperglycemic constituents were identified to support the traditional usage of H. erinaceus. MATERIALS AND METHODS: The components of H. erinaceus were purified using various column chromatography techniques. The structure of the separated compounds was determined based on spectroscopic data analysis, i.e., 1D and 2D NMR analysis. The anti-hyperglycemic activity of the isolated compounds was evaluated by measuring the inhibitory effects on alpha-glucosidase activity. Molecular docking analysis was also conducted for elucidation of alpha-glucosidase inhibitory activity of isolated compounds. RESULTS: Ten compounds including four new compounds, erinacenols A-D (1-4), were isolated from the fruiting bodies of H. erinaceus. Investigation of the anti-hyperglycemic effect of isolated compounds demonstrated that erinacenol D (4), 4-[3',7'-dimethyl-2',6'-octadienyl]-2-formyl-3-hydroxy-5-methyoxybenzylalcohol (6), hericene A (7), hericene D (8) and Hericenone D (9) strongly inhibited alpha-glucosidase activity with IC(50) values of <20 muM. The structure activity relationship suggested the importance of long side chain for alpha-glucosidase inhibitory activity. Further analysis by molecular docking demonstrated the interaction of alpha-glucosidase and isolated compounds, which supported the inhibitory activity of alpha-glucosidase. CONCLUSION: Our present study demonstrated the beneficial effect of H. erinaceus by characterization of alpha-glucosidase inhibitory compounds, including four new compounds. This approach can be valuable support for the traditional use of H. erinaceus for the treatment of diabetes and metabolic diseases, which needs to be clarified by further in-vivo study.
Anti-obesity activity of Yamabushitake (Hericium erinaceus) powder in ovariectomized mice, and its potentially active compounds.[Pubmed:28181079]
J Nat Med. 2017 Jul;71(3):482-491.
Hericium erinaceus (H. erinaceus) improves the symptoms of menopause. In this study, using ovariectomized mice as a model of menopause, we investigated the anti-obesity effect of this mushroom in menopause. Mice fed diets containing H. erinaceus powder showed significant decreases in the amounts of fat tissue, plasma levels of total cholesterol, and leptin. To determine the mechanism, groups of mice were respectively fed a diet containing H. erinaceus powder, a diet containing ethanol extract of H. erinaceus, and a diet containing a residue of the extract. As a result, H. erinaceus powder was found to increase fecal lipid levels in excreted matter. Further in vitro investigation showed that ethanol extract inhibited the activity of lipase, and four lipase-inhibitory compounds were isolated from the extract: hericenone C, Hericenone D, hericenone F, and hericenone G. In short, we suggest that H. erinaceus has an anti-obesity effect during menopause because it decreases the ability to absorb lipids.
Chemical constituents of Hericium erinaceum associated with the inhibitory activity against cellular senescence in human umbilical vascular endothelial cells.[Pubmed:25676326]
J Enzyme Inhib Med Chem. 2015 Dec;30(6):934-40.
Hericium erinaceum is an edible and medicinal mushroom widely used in Korea, Japan, and China. On the search for biologically active compounds supporting the medicinal usage, the MeOH extract of the fruiting bodies of H. erinaceum was investigated for its chemical constituents. Six compounds were isolated and identified as Hericenone D (1), (22E,24R)-5alpha,8alpha-epidioxyergosta-6,22-dien-3beta-ol (2), erinacerin B (3), hericenone E (4), hericenone F (5) and isohericerin (6) by comparing their spectroscopic data with previously reported values. The inhibitory effects on adriamycin-induced cellular senescence in human dermal fibroblasts (HDFs) and human umbilical vein endothelial cells (HUVECs) of the isolates (1-6) were studied. Among the isolated compounds, ergosterol peroxide (2) reduced senescence associated beta-galactosidase (SA-beta-gal) activity increased in HUVECs treated with adriamycin. According to experimental data obtained, the active compound may inspire the development of a new pharmacologically useful substance to be used in the treatment and prevention of age-related diseases.
